Compare Adaptive Biotechnologies Corp (ADPT) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs DoorDash Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.01 (market cap $3.33B), while DoorDash Inc trades at $185.21 (market cap $85.28B). The key difference: DoorDash Inc is far larger — about 25.6× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | DASH | |
|---|---|---|
Market Cap | $3.33B | $85.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $281.74 |
52-Week Low | $10.24 | $146.60 |
Enterprise Value | $3.19B | $83.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DoorDash (DASH) trades at $195.72, up 1.93% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $13.72B in 2025, with net income reaching $935M, though recent quarters show mixed earnings performance. The stock is near resistance at $200, with RSI indicating overbought conditions. Recent news highlights AI initiatives and market dominance.
Outlook remains positive with a $231.50 consensus price target, but risks include competition and high valuation multiples. Earnings growth and international expansion are key catalysts, while inflation and execution challenges pose headwinds for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
